Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
New England Journal of Medicine · 07.09.2023 · 389 (10) · 877-888
DOI: 10.1056/nejmoa2302392 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 07.09.2023. Verfasst von Sean Wharton und 13 weiteren Autor:innen. Beteiligte Einrichtung: From McMaster University, York University, and Wharton Weight Management Clinic - all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.…. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 478-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From McMaster University, York University, and Wharton Weight Management Clinic - all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) - b…
ORCID-Profile: Kieren J Mather
Förderung
- Eli Lilly and Company
Zitieren
APA
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., Konig, M., & GZGI Investigators (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 389(10), 877-888. https://doi.org/10.1056/nejmoa2302392
Vancouver
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023;389(10):877-888. doi:10.1056/nejmoa2302392
BibTeX
@article{Wharton2023,
author = {Wharton, Sean and Blevins, Thomas and Connery, Lisa and Rosenstock, Julio and Raha, Sohini and Liu, Rong and Ma, Xiaosu and Mather, Kieren J and Haupt, Axel and Robins, Deborah and Pratt, Edward and Kazda, Christof and Konig, Manige and GZGI Investigators, GZGI Investigators},
title = {Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {10},
pages = {877--888},
doi = {10.1056/nejmoa2302392}
}
EUVIMED